AML-009 | Anomaly Foundation Wiki | Fandom
Origin: AML-009 was one of The Trapped Evilness’ creations sent to end the world, which is a demon that haunts people who sleep with their feet exposed. Occupations: Demonic Anomaly. …
Phase 2a Study of SLS009, a Highly Selective CDK9 Inhibitor, in ...
2024年11月5日 · Resistance mechanisms to VEN-based therapies include up-regulation and dependence on MCL-1 activity. We hypothesized that the addition of SLS009, a highly …
• RP2D of SLS009 30 mg IV BIW + Aza/Ven in R/R AML • Clinical activity observed with SLS009 + Aza/Ven – Primary endpoint (ORR > 20%) met – AML-MR enriched in responders – Highest …
SELLAS Announces Positive Initial Topline Phase 2a Data of SLS009 …
2023年10月16日 · SELLAS Announces Positive Initial Topline Phase 2a Data of SLS009 in Acute Myeloid Leukemia. – SLS009 Is First CDK9 Inhibitor in Combination with AZA/VEN to Achieve …
CDK9 Inhibitor SLS009 Displays Activity in Relapsed/Refractory AML
2024年6月10日 · A phase 2a study (NCT04588922) evaluating the CDK9 inhibitor SLS009 as treatment for patients with relapsed/refractory acute myeloid leukemia (AML) has completed …
FDA Grants Fast Track Designation to SLS009 in R/R AML
2024年1月11日 · The FDA has granted a fast track designation to SLS009 (formerly GFH009), a novel and highly selective CDK9 inhibitor, for the treatment of relapsed/refractory (R/R) acute …
SLS009 Generates Positive Topline Data in R/R AML and REGAL
2024年3月26日 · SLS009 elicited strong anti-leukemic activity, defined as bone marrow blast reduction of at least 50%, in approximately 67% of patients across all dose levels. The first …
SLS009: A Potential Breakthrough for Relapsed/Refractory AML …
2024年1月9日 · SLS009 is a novel investigational agent developed by SELLAS Life Sciences, specifically designed to target AML. It is a targeted agent that focuses on the WT1 protein, a …
SLS009, a CDK9 inhibitor, with azacitidine and venetoclax for R/R AML …
2024年12月9日 · Joshua Zeidner, MD, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, comments on the promising results of a study (NCT04588922) investigating the …
CDK9 Inhibitor GFH009 Advances in Phase 1 Trial in Relapsed
2022年6月28日 · The novel and highly selective CDK9 inhibitor GFH009 demonstrated encouraging tolerability in patients with advanced, relapsed/refractory acute myeloid leukemia …